FDA moves quickly toward formal Moderna EUA decision

By The Science Advisory Board staff writers

December 18, 2020 -- The U.S. Food and Drug Administration (FDA) has informed Moderna that it will work rapidly toward the issuance of an emergency use authorization (EUA) for the company's messenger RNA (mRNA) COVID-19 vaccine candidate, mRNA-1273.

The statement was given by Dr. Stephen Hahn, FDA commissioner, and Dr. Peter Marks, PhD, director of the FDA's Center for Biologics Evaluation and Research, following the December 17 meeting of the agency's Vaccines and Related Biological Products Advisory Committee (VRBPAC), which produced a positive outcome.

In addition to notifying the sponsors, the FDA also notified the U.S. Centers for Disease Control and Prevention and Operation Warp Speed of its intentions so that the execution of plans for timely vaccine distribution can begin.

FDA committee votes favorably for Moderna COVID-19 vaccine EUA
Moderna's messenger RNA (mRNA) COVID-19 vaccine candidate, mRNA-1273, received a favorable recommendation on December 17 from an advisory committee to...
Moderna's vaccine data support high efficacy, safety prior to FDA meeting
Moderna has published information supporting a 94.1% efficacy rate for its messenger RNA (mRNA) COVID-19 vaccine, mRNA-1273. The company made the data...
FDA sets advisory meeting date to discuss Moderna COVID-19 vaccine
The U.S. Food and Drug Administration (FDA) has scheduled a meeting of its Vaccines and Related Biological Products Advisory Committee for December 17...
Moderna to file COVID-19 vaccine EUA request
Moderna said it plans to request on November 30 an emergency use authorization (EUA) from the U.S. Food and Drug Administration and conditional marketing...

Copyright © 2020 scienceboard.net


Connect
Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter